Incretin-based therapies for the treatment of obesity-related diseases US$ 24.48 Min. order: 1 piece ★★★★★ 4.0 (276 reviews) Sold : Login>>
Clinical trials of subcutaneous tirzepatide, retatrutide, and US$ 28.32 Min. order: 1 piece ★★★★★ 4.8 (86 reviews) Sold : Login>>
Novo Nordisk's CagriSema: promising but not perfect | Abdullah Melhim, MD, DABOM posted on the topic US$ 26.98 Min. order: 1 piece ★★★★★ 4.5 (18 reviews) Sold : Login>>
PDF] Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial US$ 22.95 Min. order: 1 piece ★★★★★ 4.5 (224 reviews) Sold : Login>>
New trial data on CagriSema — 23% weight loss at 84 weeks in the RE-DEFINE 4 trial. CagriSema pairs semaglutide with cagrilintide, an amylin analogue. Amylin is a pancreatic hormone that slows US$ 29.23 Min. order: 1 piece ★★★★★ 4.9 (107 reviews) Sold : Login>>